Lin Xie1, Feng-Chao Jiang1, Li-Min Zhang1, Wen-Tao He1, Jian-Hua Liu1, Ming-Qiang Li1, Xue Zhang1, Shuai Xing1, Hui Guo1, Ping Zhou2. 1. Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Health, and Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China (LX, LMZ, JHL, MQL, XZ, SX, HG, PZ); Academy of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (FCJ); Department of endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (WTH). 2. Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Health, and Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China (LX, LMZ, JHL, MQL, XZ, SX, HG, PZ); Academy of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (FCJ); Department of endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (WTH). pzhou@tjh.tjmu.edu.cn jiangfc@mails.tjmu.edu.cn.
Abstract
BACKGROUND: The TLR/MyD88 signaling pathway is an important driver of inflammation and cancer and is a possible target for antitumor therapy. METHODS: We generated a MyD88 inhibitor (TJ-M2010-5), which was designed to bind to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway. We utilized a mouse model of azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colitis-associated cancer (CAC) in combination with TJ-M2010-5 administration to investigate the anti-inflammation-related cancer effect of MyD88 inhibitor in vivo. Data were analyzed with one-way and repeated measures analysis of variance. Differences in survival between groups were compared using the log rank test. All statistical tests were two-sided. RESULTS: TJ-M2010-5 inhibited MyD88 homodimerization in transfected HEK293 cells in a concentration-dependent manner and suppressed MyD88 signaling in LPS-responsive RAW 264.7 cells in vitro. In a 10-week CAC mouse model (n = 30 per group), TJ-M2010-5 treatment statistically significantly reduced AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, resulted in 0% mortality of treated mice (compared with 53% mortality of control mice), decreased cell proliferation, and increased apoptosis in colon tissue. TJ-M2010-5 treatment also inhibited production of inflammatory cytokines and chemokines (TNF-α, IL-6,G-CSF, MIP-1β, TGF-β1, IL-11, IL-17A, IL-22 and IL-23) and infiltration of immune cells (macrophages, dendritic cells, neutropihls and CD(+)4 T cells) in colon tissues of mice. CONCLUSIONS: Our findings suggest that TLR/MyD88 signaling may be a therapeutic target for CAC intervention and MyD88 inhibitors may be a promising therapeutic modality for treating patients with colitis or CAC.
BACKGROUND: The TLR/MyD88 signaling pathway is an important driver of inflammation and cancer and is a possible target for antitumor therapy. METHODS: We generated a MyD88 inhibitor (TJ-M2010-5), which was designed to bind to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway. We utilized a mouse model of azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colitis-associated cancer (CAC) in combination with TJ-M2010-5 administration to investigate the anti-inflammation-related cancer effect of MyD88 inhibitor in vivo. Data were analyzed with one-way and repeated measures analysis of variance. Differences in survival between groups were compared using the log rank test. All statistical tests were two-sided. RESULTS:TJ-M2010-5 inhibited MyD88 homodimerization in transfected HEK293 cells in a concentration-dependent manner and suppressed MyD88 signaling in LPS-responsive RAW 264.7 cells in vitro. In a 10-week CAC mouse model (n = 30 per group), TJ-M2010-5 treatment statistically significantly reduced AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, resulted in 0% mortality of treated mice (compared with 53% mortality of control mice), decreased cell proliferation, and increased apoptosis in colon tissue. TJ-M2010-5 treatment also inhibited production of inflammatory cytokines and chemokines (TNF-α, IL-6,G-CSF, MIP-1β, TGF-β1, IL-11, IL-17A, IL-22 and IL-23) and infiltration of immune cells (macrophages, dendritic cells, neutropihls and CD(+)4 T cells) in colon tissues of mice. CONCLUSIONS: Our findings suggest that TLR/MyD88 signaling may be a therapeutic target for CAC intervention and MyD88 inhibitors may be a promising therapeutic modality for treating patients with colitis or CAC.
Authors: Cornelia Voigt; Peter May; Adrian Gottschlich; Anamarija Markota; Daniel Wenk; Inga Gerlach; Sebastian Voigt; Georgios T Stathopoulos; Kristina A M Arendt; Constanze Heise; Felicitas Rataj; Klaus-Peter Janssen; Melanie Königshoff; Hauke Winter; Isabelle Himsl; Wolfgang E Thasler; Max Schnurr; Simon Rothenfußer; Stefan Endres; Sebastian Kobold Journal: Proc Natl Acad Sci U S A Date: 2017-11-17 Impact factor: 11.205
Authors: Qiong Li; Yali Chen; Daoxiang Zhang; Julie Grossman; Lin Li; Namrata Khurana; Hongmei Jiang; Patrick M Grierson; John Herndon; David G DeNardo; Grant A Challen; Jingxia Liu; Marianna B Ruzinova; Ryan C Fields; Kian-Huat Lim Journal: JCI Insight Date: 2019-10-03
Authors: Xinxia Zhu; Kevin G Burfeind; Katherine A Michaelis; Theodore P Braun; Brennan Olson; Katherine R Pelz; Terry K Morgan; Daniel L Marks Journal: J Cachexia Sarcopenia Muscle Date: 2019-01-21 Impact factor: 12.910